Breast cancer drug showdown: which one spares your memory?
NCT ID NCT00893061
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 study looked at how four different hormone therapies (anastrozole, exemestane, letrozole, and tamoxifen) affect memory in postmenopausal women with breast cancer. The 44 participants took one of these drugs for 6 to 12 months, and researchers tested their verbal memory and other thinking skills. The goal was to find out which treatment has the least impact on memory, helping women and their doctors make more informed choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anastrozole, exemestane, letrozole, tamoxifen citrate
What this could lead to
If successful, this study could help doctors choose breast cancer treatments that are less likely to cause memory problems.
What could go wrong
This is a small, completed study with only 44 participants, so results may not apply to all women. It only measured short-term memory changes over 6-12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Eugene Marquis
Rennes, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Paul Strauss
Strasbourg, France